StockData
Hepion Pharmaceuticals, Inc. logo

Hepion Pharmaceuticals, Inc. (HEPA) stock

HEPAOTCPharmaceutical PreparationsFiscal year ends December 31Also trades as CTRVP
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q/A on Nov 17, 2026Score 1/30
$0.10−0.00 (-1.45%)

Close on Oct 19, 2026Market cap $7.26MP/E –Yield –

Hepion Pharmaceuticals r&d expenses

Research and development expenses are spending on new products and technology.

Hepion Pharmaceuticals's R&D Expenses for the twelve months ending Sep 30, 2026 was $255.57K. For fiscal 2025 it was $445.51K, down 96.2% from the year before. Over ten years it grew 3.6% a year on average. The highest annual figure on record is $35.64M in fiscal 2023.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$445.51K-96.2%
FY2024Dec 31, 2024$11.85M-66.8%
FY2023Dec 31, 2023$35.64M+7.1%
FY2022Dec 31, 2022$33.27M+63.1%
FY2021Dec 31, 2021$20.40M+70.0%
FY2020Dec 31, 2020$12.00M+276.8%
FY2019Dec 31, 2019$3.18M-76.7%
FY2017Jun 30, 2017$13.65M-9.1%
FY2016Jun 30, 2016$15.02M+78.7%
FY2015Jun 30, 2015$8.40M+2574.2%
FY2014Jun 30, 2014$314.25K–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q3 FY2026CQ3 2026Sep 30, 2026$134.65K–
Q2 FY2026CQ2 2026Jun 30, 2026$50.92K-88.0%
Q1 FY2026CQ1 2026Mar 31, 2026$70.00K+214.8%
Q4 FY2025CQ4 2025Dec 31, 2025$0-100.0%
Q3 FY2025CQ3 2025Sep 30, 2025$0-100.0%
Q2 FY2025CQ2 2025Jun 30, 2025$423.28K-83.3%
Q1 FY2025CQ1 2025Mar 31, 2025$22.24K-99.6%
Q3 FY2024CQ3 2024Sep 30, 2024$2.76M-67.6%
Q2 FY2024CQ2 2024Jun 30, 2024$7.14M-39.9%
Q1 FY2024CQ1 2024Mar 31, 2024$2.54M-74.1%
Q4 FY2023CQ4 2023Dec 31, 2023$5.44M-27.6%
Q3 FY2023CQ3 2023Sep 30, 2023$8.52M+48.4%
Q2 FY2023CQ2 2023Jun 30, 2023$11.88M-24.3%
Q1 FY2023CQ1 2023Mar 31, 2023$9.80M+127.3%
Q4 FY2022CQ4 2022Dec 31, 2022$7.52M+8.8%
Q3 FY2022CQ3 2022Sep 30, 2022$5.74M-1.0%
Q2 FY2022CQ2 2022Jun 30, 2022$15.70M+275.1%
Q1 FY2022CQ1 2022Mar 31, 2022$4.31M+23.2%
Q4 FY2021CQ4 2021Dec 31, 2021$6.91M+163.0%
Q3 FY2021CQ3 2021Sep 30, 2021$5.80M+53.3%
Q2 FY2021CQ2 2021Jun 30, 2021$4.19M+41.9%
Q1 FY2021CQ1 2021Mar 31, 2021$3.50M+32.7%
Q4 FY2020CQ4 2020Dec 31, 2020$2.63M+146.9%
Q3 FY2020CQ3 2020Sep 30, 2020$3.78M+346.9%
Q2 FY2020CQ2 2020Jun 30, 2020$2.95M+290.4%
Q1 FY2020CQ1 2020Mar 31, 2020$2.64M+409.1%
Q4 FY2019CQ4 2019Dec 31, 2019$1.06M-67.4%
Q3 FY2019CQ3 2019Sep 30, 2019$846.45K-71.3%
Q2 FY2019CQ2 2019Jun 30, 2019$755.66K-82.5%
Q1 FY2019CQ1 2019Mar 31, 2019$518.04K-83.4%
Q4 FY2017CQ2 2017Jun 30, 2017$3.26M-19.0%
Q3 FY2017CQ1 2017Mar 31, 2017$2.94M-7.6%
Q2 FY2017CQ4 2016Dec 31, 2016$4.32M+6.8%
Q1 FY2017CQ3 2016Sep 30, 2016$3.13M-16.9%
Q4 FY2016CQ2 2016Jun 30, 2016$4.02M+12.1%
Q3 FY2016CQ1 2016Mar 31, 2016$3.19M–
Q2 FY2016CQ4 2015Dec 31, 2015$4.04M–
Q1 FY2016CQ3 2015Sep 30, 2015$3.77M–
Q4 FY2015CQ2 2015Jun 30, 2015$3.59M–

More Hepion Pharmaceuticals figures

See a number that looks wrong?